ArticleVeterinary dermatology2025
Efficacy of a chewable tablet containing sarolaner, moxidectin and pyrantel for the treatment of generalised demodicosis in dogs.
Article in Veterinary dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of a chewable tablet containing sarolaner, moxidectin and pyrantel for the treatment of generalised demodicosis in dogs.Veterinary dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDemodicosis is common in dogs and is caused by proliferation of commensal Demodex canis mites.
objectiveTo evaluate the efficacy of sarolaner in combination with moxidectin and pyrantel (SMP) for the treatment of generalised demodicosis in dogs. ANIMALS: One hundred and thirty dogs with generalised demodicosis. MATERIALS AND
methodsIn two separate randomised masked studies (laboratory and field studies), dogs received monthly oral SMP or afoxolaner + milbemycin oxime (AM). In the laboratory study, dogs received three monthly treatments with biweekly mite counts and clinical evaluations. In the field study, mite counts and clinical evaluations were performed monthly and treatments were administered until two consecutive skin scrapings were negative.
resultsBoth products were tolerated well. In the laboratory study, mite counts for SMP were significantly (p < 0.001) reduced by 88.8% on Day (D)14, by 99.2% on D29, and no live mites were detected thereafter with no statistically significant difference (p = 0.96) between the two treatment groups. In the field study, SMP provided 92.4%, 98.1%, 100% and 100% reduction in arithmetic mean live mite counts on D30, D60, D90 and D120, and was non-inferior to the control product on D30 and D60. Clinical signs of demodicosis improved in all dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Monthly administration of SMP was effective for the treatment of generalised demodicosis in dogs as it eliminated Demodex mites after two monthly treatments in the laboratory study, and at most after three monthly treatments in the field study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.